Arrowstreet Capital Limited Partnership Has $151.42 Million Stake in Edwards Lifesciences Corporation $EW

Arrowstreet Capital Limited Partnership raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 341.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,890,859 shares of the medical research company’s stock after buying an additional 1,462,238 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Edwards Lifesciences were worth $151,420,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $266,000. NewEdge Advisors LLC grew its holdings in shares of Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. increased its stake in shares of Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares in the last quarter. Squarepoint Ops LLC grew its holdings in Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in shares of Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after purchasing an additional 1,065 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research report on Wednesday, April 1st. Truist Financial boosted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Evercore reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $99.55.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president owned 33,934 shares in the company, valued at $2,816,861.34. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,577 shares of company stock valued at $3,855,527 over the last 90 days. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 1.4%

Edwards Lifesciences stock opened at $82.67 on Friday. The stock has a market capitalization of $47.60 billion, a PE ratio of 47.51, a price-to-earnings-growth ratio of 2.07 and a beta of 0.86. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $87.73 and a 200-day moving average of $83.88.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same period last year, the business earned $0.67 EPS. The business’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.